Trial in progress: A phase 1B/2 study of GB5121, a novel, highly selective, potent, and CNS-penetrant inhibitor of Bruton’s tyrosine kinase (BTKI) for relapsed/refractory primary/secondary CNS lymphoma (R/R PCNSL/SCNSL) and primary vitreoretinal lymphoma (PVRL) Meeting Abstract


Authors: Soussain, C.; Grommes, C.; Issa, S.; Ward, R.; Peterson, C.; Cravets, M.; Mathias, A.; Sosa, J.; Kirby, B.; Ding, Z.; Yusuf, I.; Rose, M.; Steinberg, M.; Tun, H. W.
Abstract Title: Trial in progress: A phase 1B/2 study of GB5121, a novel, highly selective, potent, and CNS-penetrant inhibitor of Bruton’s tyrosine kinase (BTKI) for relapsed/refractory primary/secondary CNS lymphoma (R/R PCNSL/SCNSL) and primary vitreoretinal lymphoma (PVRL)
Meeting Title: 2nd Annual Conference on CNS Clinical Trials and Brain Metastases
Journal Title: Neuro-Oncology Advances
Volume: 4
Issue: Suppl. 1
Meeting Dates: 2022 Aug 11-12
Meeting Location: Toronto, Canada
ISSN: 2632-2498
Publisher: Oxford University Press  
Date Published: 2022-08-01
Start Page: i9
Language: English
DOI: 10.1093/noajnl/vdac078.035
PROVIDER: manual
Notes: Meeting Abstract: CLRM-15 -- Co-Sponsored by SNO and ASCO
Altmetric
Citation Impact
MSK Authors
  1. Christian Grommes
    99 Grommes
Related MSK Work